DelistingNov 2, 2026, 11:01 AM
Supernus Pharmaceuticals Delists From Nasdaq Following Merger Completion
AI Summary
Supernus Pharmaceuticals, Inc. has notified Nasdaq of its delisting following the consummation of a Merger on November 2, 2026. The company requested the suspension of trading for its common stock and will file a Form 25 for delisting and deregistration. Subsequently, Supernus plans to file a Form 15 to suspend its public reporting obligations, meaning its common stock will no longer be listed on any national securities exchange.
Key Highlights
- Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of the Merger.
- Trading of Supernus Common Stock was suspended effective prior to the opening of trading on November 2, 2026.
- Nasdaq will file a Form 25 to delist Supernus Common Stock and deregister it under Section 12(b) of the Exchange Act.
- The Company intends to file a Form 15 to deregister the stock under Section 12(g) and suspend reporting obligations.
- Supernus Common Stock will no longer be listed on any national securities exchange as a result of the Merger.
Price Impact
More from SUPN